MX343803B - Complejo de ipp como marcador para tratamiento de erlotinib. - Google Patents

Complejo de ipp como marcador para tratamiento de erlotinib.

Info

Publication number
MX343803B
MX343803B MX2013004037A MX2013004037A MX343803B MX 343803 B MX343803 B MX 343803B MX 2013004037 A MX2013004037 A MX 2013004037A MX 2013004037 A MX2013004037 A MX 2013004037A MX 343803 B MX343803 B MX 343803B
Authority
MX
Mexico
Prior art keywords
marker
erlotinib treatment
ipp
complex
ipp complex
Prior art date
Application number
MX2013004037A
Other languages
English (en)
Other versions
MX2013004037A (es
Inventor
Angélique Augustin
Guillemette Duchateau-Nguyen
Laurent Essioux
Sabrina Golling
Barbara Klughammer
Jens Lamerz
Hanno Langen
Hélène Meistermann
Stefan Scheiblich
Manuel Tzouros
Original Assignee
F Hoffmann-La Roche Ag *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann-La Roche Ag * filed Critical F Hoffmann-La Roche Ag *
Publication of MX2013004037A publication Critical patent/MX2013004037A/es
Publication of MX343803B publication Critical patent/MX343803B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Abstract

La presente invención se refiere a biomarcadores que son predictivos por el beneficio clínico del tratamiento con clorhidrato de erlotinib en pacientes con cáncer.
MX2013004037A 2010-10-15 2011-10-12 Complejo de ipp como marcador para tratamiento de erlotinib. MX343803B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10187683 2010-10-15
EP11173835 2011-07-13
PCT/EP2011/067757 WO2012049192A1 (en) 2010-10-15 2011-10-12 Ipp complex as marker for erlotinib treatment

Publications (2)

Publication Number Publication Date
MX2013004037A MX2013004037A (es) 2013-06-05
MX343803B true MX343803B (es) 2016-11-23

Family

ID=45934666

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004037A MX343803B (es) 2010-10-15 2011-10-12 Complejo de ipp como marcador para tratamiento de erlotinib.

Country Status (11)

Country Link
US (1) US20120095029A1 (es)
EP (1) EP2628011B1 (es)
JP (1) JP6096664B2 (es)
KR (1) KR20130139286A (es)
CN (1) CN103261894B (es)
BR (1) BR112013009143A2 (es)
CA (1) CA2813279A1 (es)
HK (1) HK1184221A1 (es)
MX (1) MX343803B (es)
RU (1) RU2600828C2 (es)
WO (1) WO2012049192A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101384686B1 (ko) 2013-05-28 2014-04-21 주식회사 바이오인프라 Egfr 표적 치료제에 대한 폐암의 치료 반응성을 예측하는 방법
CN110494570A (zh) 2017-03-29 2019-11-22 中美冠科生物技术（太仓）有限公司 确定癌症对卡仑尼替星敏感性的系统和方法
WO2019147552A1 (en) 2018-01-25 2019-08-01 The Cleveland Clinic Foundation Compounds for treating ilk-mediated diseases
CN109385477A (zh) * 2018-08-06 2019-02-26 上海市肺科医院 Ilk基因作为肺鳞癌生物标志物及治疗靶点的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5795716A (en) 1994-10-21 1998-08-18 Chee; Mark S. Computer-aided visualization and analysis system for sequence evaluation
ATE477495T1 (de) * 2005-03-16 2010-08-15 Osi Pharm Inc Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor
US8383357B2 (en) * 2005-03-16 2013-02-26 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors

Also Published As

Publication number Publication date
HK1184221A1 (zh) 2014-01-17
US20120095029A1 (en) 2012-04-19
MX2013004037A (es) 2013-06-05
JP6096664B2 (ja) 2017-03-15
CN103261894A (zh) 2013-08-21
KR20130139286A (ko) 2013-12-20
EP2628011A1 (en) 2013-08-21
RU2600828C2 (ru) 2016-10-27
CN103261894B (zh) 2016-03-16
WO2012049192A1 (en) 2012-04-19
JP2013542431A (ja) 2013-11-21
BR112013009143A2 (pt) 2016-07-26
CA2813279A1 (en) 2012-04-19
EP2628011B1 (en) 2016-12-21
RU2013119459A (ru) 2014-11-20

Similar Documents

Publication Publication Date Title
MX2013002084A (es) Biomarcadores y metodos de tratamiento.
HK1210230A1 (en) Methods, kits and compositions for providing a clinical assessment of prostate cancer
EA201171367A1 (ru) Винилиндазолильные соединения
HK1254859A1 (zh) 治療乳腺癌的方法
PT3418281T (pt) Pirazolo[1,5-a]pirimidinas úteis como inibidores da quinase atr para o tratamento de doenças de cancro
IL220129A0 (en) Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the tratment of cancer and immune diseases
WO2010017515A3 (en) Breast cancer specific markers and methods of use
SG10201510470WA (en) Use of myeloid cell biomarkers for the diagnosis of cancer
IL264349B1 (en) Regimens containing neratinib for the treatment of cancer
HK1199290A1 (en) Methods and compositions for the treatment and diagnosis of breast cancer
IL213761A0 (en) Novel ortho-aminoamides for the treatment of cancer
HRP20160851T1 (hr) Prediktori za liječenje karcinoma
EA201890598A3 (ru) Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты
HK1185874A1 (zh) 用於治療癌症的新的 -氨基- -羥基-苯甲酰胺
IL222844A0 (en) Biomarkers for the treatment of psoriasis
GB201608839D0 (en) Biomarkers useful for detectionof types, grades and stages of human breast cancer
ZA201300762B (en) Novel combination therapy for the treatment of cancer
SG11201400919RA (en) Patient stratification and determining clinical outcome for cancer patients
SG11201402115TA (en) Methods for diagnosis and/or prognosis of gynecological cancer
MX343803B (es) Complejo de ipp como marcador para tratamiento de erlotinib.
HK1204481A1 (en) Method for in vitro diagnosis or prognosis of colon cancer
MX2010001571A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.
EP2649225A4 (en) BIOMARKERS FOR THE PREDICTION OF BREAST CANCER
WO2012037553A9 (en) Use of pkc-iota inhibitors for the treatment of breast cancer
MX2010001577A (es) Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico.

Legal Events

Date Code Title Description
FG Grant or registration